Drug intelligence / Profile preview

18F-BMS-986192

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-BMS-986192 is a PET imaging tracer consisting of a programmed cell death ligand 1 (PD-L1) adnectin labeled with fluorine-18. It was developed by Bristol Myers Squibb for non-invasive imaging and quantification of PD-L1 expression in tumors. This tracer enables assessment of PD-L1 status which may help predict response to immune checkpoint inhibitor therapies. Pharmacokinetic studies show that a single-tissue reversible compartment model best describes its kinetics in tumors, with SUV measurements at 60 minutes post-injection serving as a good surrogate for quantifying tumor tracer uptake.

Other names: [18F]BMS-986192

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on 18F-BMS-986192.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-BMS-986192.

Explore the full profile